Rx Vigilance (The Professional Drug & Health Reference Tool)

Rx Vigilance (The Professional Drug & Health Reference Tool)

iOS Universal Medical

$199.99

Own Want Buy Buy

Rx Vigilance - a reference tool for health care professionals that features information on drugs and health - can now be accessed from anywhere.

Access to the all application features is included for a period of one year. At the end of the year, part of the application is turned off (access to the drug monographs and profile analysis function). The travel information, natural products section and the phonebook section remains active forever. It can be renewed year after year through In-App Purchase.

After installation, THE APPLICATION RESIDES ENTIRELY ON THE DEVICE and does not require an Internet connection for regular use. Internet access is required for updates.

Already used by thousands of physicians, pharmacists, nurses and other health care professionals across Canada, Rx Vigilance provides you with relevant and up to date information from several dozen leading reference sources. Drug monographs, pharmacological profile analysis, and information on natural products and travel destinations are among some of the many features you can now access through your device.

Our team of health care professionals is well aware of your day to day information needs. As a result, they are equipped to select what is most useful and relevant for you and your practice and to integrate that information to Rx Vigilance. In short, you will be able to access what you need quickly and effectively.

The Rx Vigilance App includes access to:

**COMPARATIVE CHARTS** (NEW)
In the application users will find a series of charts comparing the characteristics of products from the same pharmacological class in order to help them make the best therapeutic decision based on onset of action or the number of administrations a day, for example.

MONOGRAPHS
Professional information on more than 1200 drugs. You can find information on: adverse reactions, official and unofficial indications, adult dosages, paediatric dosages, geriatric dosages, adjustments for renal and hepatic impairment, precautions in pregnancy/breastfeeding, special precautions (grapefruit, stability, food, etc.), contraindications, interactions and kinetics. Monographs are regularly updated with information deemed relevant by our team of professionals.

TRAVEL
This feature allows to search for over 200 destinations. It provides access to brief and relevant overview of the destination (currency, languages, population, capital), required and/or recommended immunizations by country, recommendations based on diseases found in each country and contact details for service centres that may be of use while traveling.

NATURAL PRODUCTS
Information on more than 60 of the most commonly used natural products. It includes product indications (classified by evidence of effectiveness), product description and discussion on product safety and efficacy.

PROFILE ANALYSIS
Profile analysis allows to identify interactions and provides a description of the interactions as well as recommendations. Interactions are classified by importance of actions to be taken by the professional.

BULLETINS
Monthly communiqué for subscribers with details on the most recent updates and new developments and a list of monographs to which changes have been made. It is possible to refer to bulletins from prior months and send questions or comments via e-mail to the Rx Vigilance team.

PHONE DIRECTORY
A phone directory that consists of over 6000 useful contacts such as: hospitals, CLSCs, support groups and self-help groups, pharmacies, pharmaceutical companies, etc. It allows users to dial phone numbers directly from their iPhone and to acces links to internet sites when available.

What's New

August 2015 monthly update

QT interval
This month, several changes have been made to the information we have on the risks associated with QT interval prolongation. Warnings pertaining to the risk factors associated with QT interval prolongation (other than those that are drug-induced) have been modified in the product monographs in question.
A comprehensive revision of the document entitled "Drugs that can prolong the QT interval" has also been performed. Ceritinib has been added to the list of drugs associated with a potential risk for torsades de pointes.
Note that a link has been added to the Interactions section of each of the products monographs concerned.

Contraindications section of product monographs
The Contraindications section of our monographs has a new name. In an effort to more accurately reflect the information found in this section, it will now be known as Warnings.

FDA drops pregnancy categories
In an ongoing effort to improve prescription drug labeling, the FDA has decided to eliminate the categories used to classify the risks of using prescription drugs during pregnancy from product monographs. In fact, the categories are not always viewed as accurate, are inadequate when it comes to establishing the risk associated with using a prescription drug during pregnancy, are not updated regularly, do not include recent information and can lead to improper use of medications.
Since June 30, 2015, American manufacturers should provide details based on certain criteria in the pregnancy and breastfeeding section of their monographs. The new rules will be gradually applied to monographs that have already been published.
This information will therefore be removed from the Pregnancy section of our product monographs.


New monograph
=========================
Deferiprone (Ferriprox)
Ivermectin (Rosiver)
Pembrolizumab (Keytruda)
Tiotropium + Olodaterol (Inspiolto)

My Rating

App Store Rating

Top 200 Recent Activity

All Time Peak